nach oben

Erschienen in:

30.12.2022 | original article

Beneficial effects of Helicobacter pylori eradication in systemic sclerosis patients

verfasst von: Mislav Radić, MD PhD, Dušanka Martinović Kaliterna, Damir Bonacin, Jadranka Morović Vergles, Josipa Radić, Damir Fabijanić, Vedran Kovačić

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 15-16/2023

Einloggen, um Zugang zu erhalten

Summary

Objective

Previous studies have shown that Helicobacter pylori (HP) infection is associated with increased activity and severity of systemic sclerosis (SSc), hence we aimed to evaluate the effect of HP eradication on various symptoms and inflammatory indices.

Methods

The SSc patients without dyspeptic symptoms were prospectively enrolled in this 18-month cross-sectional study. Patients were divided into two groups based on determination of HP infection. The infected group was treated in accordance with the current HP eradication protocol. Assessment of disease activity, severity and organ involvement was performed every 6 months.

Results

A total of 42 consecutive SSc patients without dyspepsia and variable disease activity and severity were recruited. Levels of modified Rodnan skin score, erythrocyte sedimentation rate (ESR) and C reactive protein (CRP) significantly decreased following HP eradication (p < 0.001, p < 0.001 and p = 0.001, respectively), and in the HP-negative patient group ESR and CRP values increased (p = 0.03, p = 0.002). Eradication of HP in the group of infected patients induced progressive and significant improvement of disease activity and severity over time compared to baseline (p < 0.01, p < 0.001, respectively), whereas in the HP-negative patient group these scores remained unchanged. In our study, HP eradication was associated with an improvement of clinical symptoms and disease activity.

Conclusion

These findings suggest that HP detection and subsequent eradication could be beneficial in the management of SSc patients. Although, HP eradication seems to be advantageous in infected SSc patients, larger controlled studies are needed for a potential recommendation.

Vorheriger Artikel Management of suspected and known eosinophilic esophagitis—a nationwide survey in Austria

Nächster Artikel Prevalence and dynamics of NAFLD-associated fibrosis in people living with HIV in Vienna from first presentation to last follow-up

Radić M, Kaliterna DM, Radić J. Helicobacter pylori infection and systemic sclerosis-is there a link? Joint Bone Spine. 2011;78:337–40. https://doi.org/10.1016/j.jbspin.2010.10.005.CrossRefPubMed

Yong WC, Upala S, Sanguankeo A. Helicobacter pylori infection in systemic sclerosis: a systematic review and meta-analysis of observational studies. Clin Exp Rheumatol. 2018;36(Suppl 113):168–74.PubMed

Radić M. Role of Helicobacter pylori infection in autoimmune systemic rheumatic diseases. World J Gastroenterol. 2014;20:12839–46. https://doi.org/10.3748/wjg.v20.i36.12839.CrossRefPubMedPubMedCentral

Radić M, Martinović Kaliterna D, Bonacin D, Morović Vergles J, Radić J. Correlation between Helicobacter pylori infection and systemic sclerosis activity. Rheumatology. 2010;49:1784–5. https://doi.org/10.1093/rheumatology/keq137.CrossRefPubMed

Radić M, Kaliterna DM, Bonacin D, Vergles JM, Radić J, Fabijanić D, Kovačić V. Is Helicobacter pylori infection a risk factor for disease severity in systemic sclerosis? Rheumatol Int. 2013;33:2943–8. https://doi.org/10.1007/s00296-012-2585-z.CrossRefPubMed

van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden RP, Medsger TA Jr, Carreira PE, Riemekasten G, Clements PJ, Denton CP, Distler O, Allanore Y, Furst DE, Gabrielli A, Mayes MD, van Laar JM, Seibold JR, Czirjak L, Steen VD, Inanc M, Kowal-Bielecka O, Müller-Ladner U, Valentini G, Veale DJ, Vonk MC, Walker UA, Chung L, Collier DH, Csuka ME, Fessler BJ, Guiducci S, Herrick A, Hsu VM, Jimenez S, Kahaleh B, Merkel PA, Sierakowski S, Silver RM, Simms RW, Varga J, Pope JE. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65:2737–47. https://doi.org/10.1002/art.38098.CrossRefPubMedPubMedCentral

LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Rowell N, Wollheim F. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15:202–5.PubMed

Medsger TA Jr, Bombardieri S, Czirjak L, Scorza R, Della Rossa A, Bencivelli W. Assessment of disease severity and prognosis. Clin Exp Rheumatol. 2003;21(3 Suppl 29):S42–S6.PubMed

Valentini G, Rossa DA, Bombardieri S, Bencivelli W, Silman AJ, D’Angelo S, Cerinic MM, Belch JF, Black CM, Bruhlmann P, Czirják L, De Luca A, Drosos AA, Ferri C, Gabrielli A, Giacomelli R, Hayem G, Inanc M, McHugh NJ, Nielsen H, Rosada M, Scorza R, Stork J, Sysa A, van den Hoogen FH, Vlachoyiannopoulos PJ. European multicentre study to define disease activity for systemic sclerosis. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis. 2001;60:592–8. https://doi.org/10.1136/ard.60.6.592.CrossRefPubMedPubMedCentral

10.

Savarino V, Mela GS, Zentilin P, Bisso G, Pivari M, Mansi C, Mele MR, Bilardi C, Vigneri S, Celle G. Comparison of isotope ratio mass spectrometry and nondispersive isotope-selective infrared spectroscopy for 13C-urea breath test. Am J Gastroenterol. 1999;94:1203–8. https://doi.org/10.1111/j.1572-0241.1999.01067.x.CrossRefPubMed

11.

Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ, European Helicobacter Study Group. Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report. Gut. 2012;61:646–64. https://doi.org/10.1136/gutjnl-2012-302084.CrossRefPubMed

12.

Steen VD. Treatment of systemic sclerosis. Am J Clin Dermatol. 2001;2:315–25. https://doi.org/10.2165/00128071-200102050-00006.CrossRefPubMed

13.

Richard N, Hudson M, Gyger G, Baron M, Sutton E, Khalidi N, Pope JE, Carrier N, Larché M, Albert A, Fortin PR, Thorne C, Masetto A, on the behalf of Canadian Scleroderma Research Group. Clinical correlates of faecal incontinence in systemic sclerosis: identifying therapeutic avenues. Rheumatology. 2017;56:581–8. https://doi.org/10.1093/rheumatology/kew441.CrossRefPubMed

14.

Grossman C, Dovrish Z, Shoenfeld Y, Amital H. Do infections facilitate the emergence of systemic sclerosis? Autoimmun Rev. 2011;10:244–7. https://doi.org/10.1016/j.autrev.2010.09.010.CrossRefPubMed

15.

Bilgin H, Kocabaş H, Keşli R. The prevalence of infectious agents in patients with systemic sclerosis. Turk J Med Sci. 2015;45:1192–7.CrossRefPubMed

16.

Royle JG, Lanyon PC, Grainge MJ, Abhishek A, Pearce FA. The incidence, prevalence, and survival of systemic sclerosis in the UK Clinical Practice Research Datalink. Clin Rheumatol. 2018;37:2103–11. https://doi.org/10.1007/s10067-018-4182-3.CrossRefPubMedPubMedCentral

17.

Efthymiou G, Dardiotis E, Liaskos C, Marou E, Tsimourtou V, Scheper T, Meyer W, Daponte A, Sakkas LI, Hadjigeorgiou G, Bogdanos DP. Anti-hsp60 antibody responses based on Helicobacter pylori in patients with multiple sclerosis: (ir)Relevance to disease pathogenesis. J Neuroimmunol. 2016;298:19–23. https://doi.org/10.1016/j.jneuroim.2016.06.009.CrossRefPubMed

18.

Narang M, Puri AS, Sachdeva S, Singh J, Kumar A, Saran RK. Celiac disease and Helicobacter pylori infection in children: is there any Association? J Gastroenterol Hepatol. 2017;32:1178–82. https://doi.org/10.1111/jgh.13654.CrossRefPubMed

19.

Thia KT, Loftus EV Jr, Sandborn WJ, Yang SK. An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol. 2008;103:3167–82. https://doi.org/10.1111/j.1572-0241.2008.02158.x.CrossRefPubMed

20.

Bravo D, Hoare A, Soto C, Valenzuela MA, Quest AF. Helicobacter pylori in human health and disease: mechanisms for local gastric and systemic effects. World J Gastroenterol. 2018;24:3071–89. https://doi.org/10.3748/wjg.v24.i28.3071.CrossRefPubMedPubMedCentral

21.

Andréasson K, Alrawi Z, Persson A, Jönsson G, Marsal J. Intestinal dysbiosis is common in systemic sclerosis and associated with gastrointestinal and extraintestinal features of disease. Arthritis Res Ther. 2016;18:278. https://doi.org/10.1186/s13075-016-1182-z.CrossRefPubMedPubMedCentral

22.

Volkmann ER, Chang YL, Barroso N, Furst DE, Clements PJ, Gorn AH, Roth BE, Conklin JL, Getzug T, Borneman J, McGovern DP, Tong M, Jacobs JP, Braun J. Association of systemic sclerosis with a unique colonic microbial consortium. Arthritis Rheumatol. 2016;68:1483–92. https://doi.org/10.1002/art.39572.CrossRefPubMedPubMedCentral

Titel: Beneficial effects of Helicobacter pylori eradication in systemic sclerosis patients
verfasst von: Mislav Radić, MD PhD
Dušanka Martinović Kaliterna
Damir Bonacin
Jadranka Morović Vergles
Josipa Radić
Damir Fabijanić
Vedran Kovačić
Publikationsdatum: 30.12.2022
Verlag: Springer Vienna
Erschienen in: Wiener klinische Wochenschrift / Ausgabe 15-16/2023
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI: https://doi.org/10.1007/s00508-022-02142-8

Springer Medizin Österreich

Summary

Objective

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 15-16/2023

Global prevalence of constipation in older adults: a systematic review and meta-analysis

MUW researcher of the month

Technical and functional outcome after sacral neuromodulation using the “H” technique

Clinical-Pathological Conference Series from the Medical University of Graz

Prevalence and dynamics of NAFLD-associated fibrosis in people living with HIV in Vienna from first presentation to last follow-up

Labor und Niere: Klar definiertes Vorgehen